Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

• Published in: International journal of cancer Vol. 147; no. 8; pp. 2190 - 2198
• Main Authors: Piha‐Paul, Sarina A., Oh, Do‐Youn, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin K., Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., Braud, Filippo, Varga, Andrea Iolanda, Hansen, Aaron, Wang, Hui, Krishnan, Suba, Norwood, Kevin G., Doi, Toshihiko
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 15.10.2020; Wiley Subscription Services, Inc
• Subjects: Aged; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antitumor activity; B7-H1 Antigen - metabolism; Biliary tract; biliary tract cancer; Biliary Tract Neoplasms - drug therapy; Biliary Tract Neoplasms - metabolism; Cancer; Cholangiocarcinoma; Female; Humans; Immunotherapy; Male; Medical research; Monoclonal antibodies; MSI‐H; Oncology; PD-L1 protein; PD‐L1; Pembrolizumab; Renal failure; Response Evaluation Criteria in Solid Tumors; Solid tumors; Targeted cancer therapy; Toxicity; Tumors; biliary tract cancer; PD-L1; pembrolizumab; MSI-H

We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE‐158 (NCT02628067; phase 2) and KEYNOTE‐028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that p...